🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Heikki Joensuu

Orion Corporation (Finland)

ORCID: 0000-0003-0281-2507

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer”.

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer

Nature Communications(2023)10.1038/s41467-023-37806-0

N/A

1.4DataRank · unranked

44 citations

Saranya Chumsri, Douglas Hinerfeld, Yaohua Ma, Xue Wang, David Zahrieh +21 more

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

Annals of Oncology(2020)10.1016/j.annonc.2020.08.2232

N/A

0.749DataRank · unranked

146 citations

Cristina R. Antonescu, Bodil Bjerkehagen, Judith V.M.G. Bovée, Kjetil Boye, Matías Chacón +43 more

CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis

Cancer Research(2021)10.1158/0008-5472.can-20-3651

N/A

0.596DataRank · unranked

52 citations

Srikar G. Nagelli, Caroline Farrington, Umar Butt, Anna N. Cvrljevic, Julia P. Vainonen +19 more

Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1945

N/A

0.561DataRank · unranked

41 citations

Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O. Nielsen +4 more

Polygenic risk, susceptibility genes, and breast cancer over the life course

medRxiv(2020)10.1101/2020.04.17.20069229

N/A

0.373DataRank · unranked

11 citations

Elisabeth Widén, Sini Kerminen, Tuomo J Meretoja, Matti Pirinen, Priit Palta +7 more

Large-scale genome-wide analyses with proteomics integration reveal novel loci and biological insights into frailty

Nature Aging(2025)10.1038/s43587-025-00925-y

N/A

0.269DataRank · unranked

5 citations

Chenxi Qin, Moritz Krüger, Anna Kuukka, Aarno Palotie, Mark Daly +322 more

An effective drug combination for the first-line treatment of advanced gastrointestinal stromal tumor

Annals of Palliative Medicine(2023)10.21037/apm-22-1179

N/A

0.171DataRank · unranked

2 citations

Heikki Joensuu

Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.510

N/A

0.165DataRank · unranked

2 citations

Jodi M. Carter, Yaohua Ma, Douglas Hinerfeld, Heather Ann Brauer, Sarah Warren +15 more

Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.569

N/A

0DataRank · unranked

0 citations

Yi Liu, Sachin Kumar Deshmukh, Jodi M. Carter, Heikki Joensuu, Roberto A. Leon‐Ferre +15 more